Safety, Pharmacokinetic and Pharmacodynamic Study of COR-1, an Anti-ß1 Receptor Antibody Cyclopeptide
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
Primary Trial objectives:
To evaluate the pharmacokinetics and -dynamics of five strengths of COR-1 (10, 40, 80, 160,
240 mg) in 50 healthy, male volunteers after single intravenous administration (8 subjects on
verum per dose level, 10 subjects receiving placebo)
Secondary objectives:
To evaluate safety and tolerability by using adverse events (AEs) and vital signs